Postmenopausal osteoporosis, Osteoporosis(Primary or hypogonadal in men), Osteoporosis caused by corticosteroid

Parathyroid Hormone Analog
Teriparatide is a recombinant formulation of endogenous parathyroid hormone (PTH), containing a 34-amino-acid sequence which is identical to the N-terminal portion of this hormone. The pharmacologic activity of teriparatide, which is similar to the physiologic activity of PTH, includes stimulating osteoblast function, increasing gastrointestinal calcium absorption, and increasing renal tubular reabsorption of calcium. Treatment with teriparatide results in increased bone mineral density, bone mass, and strength. In postmenopausal females, teriparatide has been shown to decrease osteoporosis-related fractures.

1.Distribution: Vd: ~0.12 L/kg.
2.Metabolism: Hepatic (nonspecific proteolysis).
3.Bioavailability: ~95%.
4.Half-life elimination: IV: 5 minutes; SubQ: ~1 hour.
5.Time to peak, serum: ~30 minutes.
6.Excretion: Urine (as metabolites).

Hypersensitivity (eg, anaphylaxis, angioedema) to teriparatide or any component of the formulation.

Adverse events were observed in animal reproduction studies; consider discontinuing treatment once pregnancy is recognized.

It is not known if teriparatide is present in breast milk.
The manufacturer recommends avoiding use in patients who are breastfeeding.

Hypotension, syncope, asthenia, nausea, dizziness, rhinitis, hyperuricemia, injection site reactions (bleeding, bruising, erythema, pain, pruritus, swelling)

Osteoporosis: SUBQ: 20 mcg once daily.